Variant · Expression
ERBB2 Overexpression
CI-VAR-00003165Explore in graph →CIViC 875
Curated evidence
Evidence by cancer (19 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29584549
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Endometrial Serous Adenocarcinoma1 | ||||||||
| ERBB2 Overexpression | Carboplatin + Paclitaxel + TrastuzumabCombination | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID7386In a randomized phase 2 trial, patients who have uterine serous carcinoma that overexpress erbb2 were allocated carboplatin-paclitaxed with or without trastuzumab. Median progression-free survival was… (full text at CIViC) PMID 29584549 · Fader et al., 2018 · Open in CIViC | civic |
| Gastroesophageal Junction Adenocarcinoma2 | ||||||||
| ERBB2 Overexpression | Ramucirumab | Predictive | B | Does Not Support Reduced Sensitivity | 2 | submitted | EID7064Given that some results in HER2 gastroesophageal cancer have shown that after first line trastuzumab, second line chemotherapy with trastuzumab (CT) is superior to chemotherapy alone, the authors comp… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available